Edgewise Therapeutics, Inc.EWTXNASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+41.0%
5Y CAGR+59.2%
Year-over-Year Change
Research and development spending
3Y CAGR
+41.0%/yr
Annual compound
5Y CAGR
+59.2%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
10.2x
Strong expansion
Streak
6 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $151.39M | +19.2% |
| 2024 | $126.97M | +39.7% |
| 2023 | $90.91M | +68.2% |
| 2022 | $54.03M | +67.9% |
| 2021 | $32.19M | +117.5% |
| 2020 | $14.80M | +71.6% |
| 2019 | $8.62M | - |